As per the International Diabetes Foundation, the number of adults suffering from diabetes was around 425 million and is expected to reach 630 million by 2045. The prevalence of diabetes is primarily increasing owing to the rapid adoption of sedentary lifestyle and unhealthy food habits.
This further shows that the demand for blood glucose monitoring systems will increase, thereby driving the global blood glucose monitoring systems market.
For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/blood-glucose-monitoring-market-100648
list of key companies mentioned in blood glucose monitoring systems market report,
- Hoffmann-La Roche Ltd.
- Ascensia Diabetes Care Holdings AG
- Dexcom, Inc.
- Braun Melsungen AG
- Lifescan Inc.
- Terumo Medical Corporation
- DiamonTech GmbH
Fortune Business Insights in a new report, titled “Blood Glucose Monitoring Systems Market Size, Share & Industry Analysis, By Device (Continuous Blood Glucose Monitoring Systems, Self-monitoring of Blood Glucose Systems), By Type (Invasive, Non-invasive), By Modality (Wearable, Non-wearable), By Distribution Channel (Institutional Sales, Retail Sales) and Regional Forecast, 2019-2026” offers an in-depth analysis of the market.
It further provides details on the adoption of blood glucose monitoring devices across several regions. Information on trends, drivers, opportunities, threats, and restraints of the market can help stakeholders to gain valuable insights into the market. The report offers a detailed competitive landscape by presenting information on key players operating in the market.
Request a Sample Copy of the Global Blood Glucose Monitoring Systems Market Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/rehabilitation-robots-market-101013
Major Segmentation includes;
- Continuous Blood Glucose Monitoring Systems
- Self-monitoring of Blood Glucose Monitoring Systems
By Distribution Channel
- Institutional Sales
- Retail Sales
This is a huge cost of burden for diabetic patients. However, the presence of favorable reimbursement healthcare policies plays a fundamental role in the high adoption of blood glucose monitoring systems. Increasing support from private as well as public health insurance agencies is expected to drive the market, especially in developed nations. this is not the case in developed economies.
For instance, the National Diabetes Services Scheme or NDSS in Australia offers SMBG devices to patients at subsidized rates. Furthermore, around 1.3 million people in Australia registered themselves with NDSS in the year 2018.
More Trending Topics from Fortune Business Insights: